Abstract: Peptides, mimetics and antibodies of erbB, TNF, and IgSF receptors and pharmaceutical compositions comprising the same are described. Methods of using such antibodies, peptides, and mimetics in therapeutic, prophylactic, imaging and diagnostic applications are disclosed.

Abstract: Peptides, mimetics and antibodies of erbB, TNF, and IgSF receptors and pharmaceutical compositions comprising the same are described. Methods of using such antibodies, peptides, and mimetics in therapeutic, prophylactic, imaging and diagnostic applications are disclosed.

Abstract: Methods for forming tungsten-containing layers on substrates are provided herein. In some embodiments, a method for forming a tungsten-containing layer on a substrate disposed in a process chamber may include mixing hydrogen and a hydride to form a first process gas; introducing the first process gas to the process chamber; exposing the substrate in the process chamber to the first process gas for a first period of time to form a conditioned substrate surface; subsequently purging the process chamber of the first process gas; exposing the substrate to a second process gas comprising a tungsten precursor for a second period of time to form a tungsten-containing nucleation layer atop the conditioned substrate surface; and subsequently purging the process chamber of the second process gas.

Abstract: Peptides, mimetics and antibodies of erbB, TNF, and IgSF receptors and pharmaceutical compositions comprising the same are described. Methods of using such antibodies, peptides, and mimetics in therapeutic, prophylactic, imaging and diagnostic applications are disclosed.

Abstract: Peptides, mimetics and antibodies of erbB, TNF, and IgSF receptors and pharmaceutical compositions comprising the same are described. Methods of using such antibodies, peptides, and mimetics in therapeutic, prophylactic, imaging and diagnostic applications are disclosed.

Abstract: Peptides, mimetics and antibodies of erbB, TNF, and IgSF receptors and pharmaceutical compositions comprising the same are described. Methods of using such antibodies, peptides, and mimetics in therapeutic, prophylactic, imaging and diagnostic applications are disclosed.

Abstract: Peptides, mimetics and antibodies of erbB, TNF, and IgSF receptors and pharmaceutical compositions comprising the same are described. Methods of using such antibodies, peptides, and mimetics in therapeutic, prophylactic, imaging and diagnostic applications are disclosed.

Abstract: Peptides, mimetics and antibodies of erbB, TNF, and IgSF receptors and pharmaceutical compositions comprising the same are described. Methods of using such antibodies, peptides, and mimetics in therapeutic, prophylactic, imaging and diagnostic applications are disclosed.

Abstract: Peptides, mimetics and antibodies of erbB, TNF, and IgSF receptors and pharmaceutical compositions comprising the same are described. Methods of using such antibodies, peptides, and mimetics in therapeutic, prophylactic, imaging and diagnostic applications are disclosed.

Abstract: Peptides, mimetics and antibodies of erbB, TNF, and IgSF receptors and pharmaceutical compositions comprising the same are described. Methods of using such antibodies, peptides, and mimetics in therapeutic, prophylactic, imaging and diagnostic applications are disclosed.

Abstract: A latex having a reduced amount of 4-phenylcyclohexene is obtainable by reacting A) 30–90% by weight of at least one ethylenically unsaturated monomer; B) 70–10% by weight of a diene; C) 1–10% by weight of ?,?-unsaturated carboxylic acids, carboxylic acid nitriles, carboxylic acid amides, or mixtures thereof; and D) an auxiliary, an additive or mixtures thereof. The reaction follows a gradient regime for components A and B.

Abstract: A latex having a reduced amount of 4-phenylcyclohexene is obtainable by reacting A) 30-90% by weight of at least one ethylenically unsaturated monomer; B) 70-10% by weight of a diene; C) 1-10% by weight of &agr;,&bgr;-unsaturated carboxylic acids, carboxylic acid nitrites, carboxylic acid amides, or mixtures thereof; and D) an auxiliary, an additive or mixtures thereof; wherein a sum of A, B and C is 100% by weight. The reaction follows a gradient regime for components A and B. In the gradient regime, an amount added per unit time of one of components A or B continuously increases, while simultaneously an amount added per unit time continuously decreases for one of components A or B which does not undergo the continuous increase; with the proviso that a starting molar ratio of A to B is adjusted from a range of 0.15-0.95 or 1.05-6.66 through at least one discontinuous change in the amount added per unit time to a target molar ratio of A to B, in the range of 1.05-6.66 or 0.15-0.

Abstract: A user-propelled walking apparatus comprising a frame assembly having a pair of front wheels and a pair of rear wheels. The pair of front wheels are maintained substantially parallel to one another. An upper body and seat assembly having a seat and a movable torso support unit is mounted to the frame assembly. The movable torso support unit is allowed to rotate or pivot. The rotation or pivoting movement of the movable torso support unit is connected to a mechanical transmission for controlling steering which controls the direction of the front wheels. A gait guide system comprising a pair of independent gait guides attached to the frame assembly to limit the movement of the user's feet. Each of the gait guides includes an elongate rail pivotally connected to the frame assembly. A sleeve is slidably mounted on the elongate rail and a shoe bracket is pivotally connected to the sleeve.